Cargando…
PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments
PPARγ is a member of the ligand-activated nuclear receptor superfamily: its ligands act as insulin sensitizers and some are approved for the treatment of metabolic disorders in humans. PPARγ has pleiotropic effects on survival and proliferation of multiple cell types, including cancer cells, and is...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586323/ https://www.ncbi.nlm.nih.gov/pubmed/19043603 http://dx.doi.org/10.1155/2008/945275 |
_version_ | 1782160888446320640 |
---|---|
author | Veliceasa, Dorina Schulze-Hoëpfner, Frank Thilo Volpert, Olga V. |
author_facet | Veliceasa, Dorina Schulze-Hoëpfner, Frank Thilo Volpert, Olga V. |
author_sort | Veliceasa, Dorina |
collection | PubMed |
description | PPARγ is a member of the ligand-activated nuclear receptor superfamily: its ligands act as insulin sensitizers and some are approved for the treatment of metabolic disorders in humans. PPARγ has pleiotropic effects on survival and proliferation of multiple cell types, including cancer cells, and is now subject of intensive preclinical cancer research. Studies of the recent decade highlighted PPARγ role as a potential modulator of angiogenesis in vitro and in vivo. These observations provide an additional facet to the PPARγ image as potential anticancer drug. Currently PPARγ is regarded as an important target for the therapies against angiogenesis-dependent pathological states including cancer and vascular complications of diabetes. Some of the studies, however, identify pro-angiogenic and tumor-promoting effects of PPARγ and its ligands pointing out the need for further studies. Below, we summarize current knowledge of PPARγ regulatory mechanisms and molecular targets, and discuss ways to maximize the beneficial activity of the PPARγ agonists. |
format | Text |
id | pubmed-2586323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-25863232008-11-28 PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments Veliceasa, Dorina Schulze-Hoëpfner, Frank Thilo Volpert, Olga V. PPAR Res Review Article PPARγ is a member of the ligand-activated nuclear receptor superfamily: its ligands act as insulin sensitizers and some are approved for the treatment of metabolic disorders in humans. PPARγ has pleiotropic effects on survival and proliferation of multiple cell types, including cancer cells, and is now subject of intensive preclinical cancer research. Studies of the recent decade highlighted PPARγ role as a potential modulator of angiogenesis in vitro and in vivo. These observations provide an additional facet to the PPARγ image as potential anticancer drug. Currently PPARγ is regarded as an important target for the therapies against angiogenesis-dependent pathological states including cancer and vascular complications of diabetes. Some of the studies, however, identify pro-angiogenic and tumor-promoting effects of PPARγ and its ligands pointing out the need for further studies. Below, we summarize current knowledge of PPARγ regulatory mechanisms and molecular targets, and discuss ways to maximize the beneficial activity of the PPARγ agonists. Hindawi Publishing Corporation 2008 2008-11-18 /pmc/articles/PMC2586323/ /pubmed/19043603 http://dx.doi.org/10.1155/2008/945275 Text en Copyright © 2008 Dorina Veliceasa et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Veliceasa, Dorina Schulze-Hoëpfner, Frank Thilo Volpert, Olga V. PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments |
title | PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments |
title_full | PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments |
title_fullStr | PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments |
title_full_unstemmed | PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments |
title_short | PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments |
title_sort | pparγ and agonists against cancer: rational design of complementation treatments |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586323/ https://www.ncbi.nlm.nih.gov/pubmed/19043603 http://dx.doi.org/10.1155/2008/945275 |
work_keys_str_mv | AT veliceasadorina ppargandagonistsagainstcancerrationaldesignofcomplementationtreatments AT schulzehoepfnerfrankthilo ppargandagonistsagainstcancerrationaldesignofcomplementationtreatments AT volpertolgav ppargandagonistsagainstcancerrationaldesignofcomplementationtreatments |